Literature DB >> 17584025

Targeting the leukemia microenvironment.

Marina Konopleva1, Michael Andreeff.   

Abstract

Normal hematopoiesis is maintained by dynamic interactions between hematopoietic cells and the bone marrow microenvironment. In hematological malignancies, there are reciprocal interactions between leukemic cells and cells of the bone marrow microenvironment such as stroma, osteoblasts and endothelium. In this review, we will discuss the influence of the microenvironment on the evolution of the leukemic phenotype. We propose that specific niches within the bone marrow microenvironment may provide a sanctuary for subpopulations of leukemic cells to evade chemotherapy-induced death and allow acquisition of a drug-resistant phenotype. We will also discuss recent studies that suggest novel therapeutic interventions targeting the microenvironment/leukemia interaction. Focus on this stroma-leukemia crosstalk may result in the development of strategies that alleviate the acquisition of a chemoresistant phenotype and enhance the efficacy of therapies in hematological malignancies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17584025     DOI: 10.2174/138945007780830827

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  23 in total

1.  Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.

Authors:  Sarah E M Herman; Amber L Gordon; Erin Hertlein; Asha Ramanunni; Xiaoli Zhang; Samantha Jaglowski; Joseph Flynn; Jeffrey Jones; Kristie A Blum; Joseph J Buggy; Ahmed Hamdy; Amy J Johnson; John C Byrd
Journal:  Blood       Date:  2011-03-21       Impact factor: 22.113

2.  Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment.

Authors:  Zhihong Zeng; Yue Xi Shi; Twee Tsao; YiHua Qiu; Steven M Kornblau; Keith A Baggerly; Wenbin Liu; Katti Jessen; Yi Liu; Hagop Kantarjian; Christian Rommel; David A Fruman; Michael Andreeff; Marina Konopleva
Journal:  Blood       Date:  2012-07-23       Impact factor: 22.113

3.  Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity.

Authors:  Amie S Corbin; Anupriya Agarwal; Marc Loriaux; Jorge Cortes; Michael W Deininger; Brian J Druker
Journal:  J Clin Invest       Date:  2010-12-13       Impact factor: 14.808

4.  Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100.

Authors:  Bruno Nervi; Pablo Ramirez; Michael P Rettig; Geoffrey L Uy; Matthew S Holt; Julie K Ritchey; Julie L Prior; David Piwnica-Worms; Gary Bridger; Timothy J Ley; John F DiPersio
Journal:  Blood       Date:  2008-12-02       Impact factor: 22.113

5.  The warburg effect in leukemia-stroma cocultures is mediated by mitochondrial uncoupling associated with uncoupling protein 2 activation.

Authors:  Ismael Samudio; Michael Fiegl; Teresa McQueen; Karen Clise-Dwyer; Michael Andreeff
Journal:  Cancer Res       Date:  2008-07-01       Impact factor: 12.701

6.  PKC-β as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates preclinical activity in CLL.

Authors:  Dalia El-Gamal; Katie Williams; Taylor D LaFollette; Matthew Cannon; James S Blachly; Yiming Zhong; Jennifer A Woyach; Erich Williams; Farrukh T Awan; Jeffrey Jones; Leslie Andritsos; Kami Maddocks; Chia-Hsien Wu; Ching-Shih Chen; Amy Lehman; Xiaoli Zhang; Rosa Lapalombella; John C Byrd
Journal:  Blood       Date:  2014-07-07       Impact factor: 22.113

7.  Triptolide induces caspase-dependent cell death mediated via the mitochondrial pathway in leukemic cells.

Authors:  Bing Z Carter; Duncan H Mak; Wendy D Schober; Teresa McQueen; David Harris; Zeev Estrov; Randall L Evans; Michael Andreeff
Journal:  Blood       Date:  2006-03-23       Impact factor: 22.113

Review 8.  Generation of erythroid cells from polyploid giant cancer cells: re-thinking about tumor blood supply.

Authors:  Zhigang Yang; Hong Yao; Fei Fei; Yuwei Li; Jie Qu; Chunyuan Li; Shiwu Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2018-02-07       Impact factor: 4.553

9.  Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction.

Authors:  Ismael Samudio; Romain Harmancey; Michael Fiegl; Hagop Kantarjian; Marina Konopleva; Borys Korchin; Kumar Kaluarachchi; William Bornmann; Seshagiri Duvvuri; Heinrich Taegtmeyer; Michael Andreeff
Journal:  J Clin Invest       Date:  2009-12-21       Impact factor: 14.808

10.  Mechanisms of resistance to decitabine in the myelodysplastic syndrome.

Authors:  Taichun Qin; Ryan Castoro; Samih El Ahdab; Jaroslav Jelinek; Xiaodan Wang; Jiali Si; Jingmin Shu; Rong He; Nianxiang Zhang; Woonbok Chung; Hagop M Kantarjian; Jean-Pierre J Issa
Journal:  PLoS One       Date:  2011-08-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.